Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

NCT01623323 is registered in ClinicalTrials.gov with Optinose US Inc. as lead sponsor.

NCT NCT01623323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01623323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Lead sponsor
Optinose US Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2013
Completion date
March 31, 2015
Enrollment
705 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic sinusitis with or without nasal polyps